Conferences - Results from #260

ESMO 2024: Invited Discussant: ETER100, TACITO, and CheckMate 9ER Trials September 15, 2024

ESMO 2024: EV-302: Exploratory Analysis of Nectin-4 Expression and Response to 1L Enfortumab Vedotin (EV) + Pembrolizumab (P) in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer (la/mUC) September 15, 2024

ESMO 2024: Anlotinib Combined with Anti-PD-L1 Antibody Benmelstobart (TQB2450) Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma -a Randomized, Open-Label, Phase III Study (ETER100) September 15, 2024

ESMO 2024: Updates in Penile Cancer September 15, 2024

ESMO 2024: ctDNA Clearance with Neoadjuvant Durvalumab + Tremelimumab + Enfortumab Vedotin for Cisplatin-Ineligible MIBC from the Safety Run-in Cohort of the Phase 3 VOLGA Trial September 15, 2024

ESMO 2024: Non-Clear Cell RCC September 15, 2024

ESMO 2024: CARE1 Pragmatic Clinical Trial - First Line Randomised Study Platform to Optimize Treatment in Patients with Metastatic Renal Cell Carcinoma September 15, 2024

ESMO 2024: Alliance A031501: AMBASSADOR Study of Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma vs Observation: Extended Follow-up DFS Results and Metastatic Disease Recurrence Distribution September 15, 2024

ESMO 2024: Invited Discussant: Improving Outcomes of Localized Urothelial Cancer September 15, 2024

ESMO 2024: T Cell Engagers in Prostate Cancer September 15, 2024

ESMO 2024: DLL-3 Targeted Therapy for Neuroendocrine Prostate Cancer September 15, 2024

ESMO 2024: Outcomes with Novel Combinations in Non-Clear Cell RCC: ORACLE Study September 15, 2024

ESMO 2024: Prospective COTRIMS (COlogne Trial of Retroperitoneal Lymphadenectomy in Metastatic Seminoma) Trial – 3 Year Update September 15, 2024

ESMO 2024: Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC Patients September 15, 2024

ESMO 2024: Does Lower Serum Testosterone Predict Metastases-Free Survival in nmCRPC Patients Treated with Novel Antiandrogens? a Post-Hoc Analysis of SPARTAN and ARAMIS September 15, 2024

ESMO 2024: Determination of Tumor PSMA Expression in Prostate Cancer from Blood Using a Novel Epigenomic Liquid Biopsy Platform September 15, 2024

ESMO 2024: Surveillance/minimal Intervention for Good Risk Disease September 15, 2024

ESMO 2024: B7-H3 as Therapeutic Target for Prostate Cancer September 15, 2024

ESMO 2024: Assessment of the Utility of CT Scans in the Long-Term Follow-up of Metastatic Non-Seminomatous Germ Cell Tumors: The Late CT Study September 14, 2024

ESMO 2024: TAMARACK: Randomized Phase 2 Trial of the B7-H3 Targeting Antibody Drug Conjugate Vobramitamab September 14, 2024

Page 14 of 594